Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. - Wikidata - awgldk - TriplyDB

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients.

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients.

http://www.wikidata.org/entity/Q34453827

about

Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research Clinical significance of human papillomavirus genotyping Perspectives for therapeutic HPV vaccine development Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice Progress and prospects for L2-based human papillomavirus vaccines Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.Combined SYBR Green real-time polymerase chain reaction and microarray method for the simultaneous determination of human papillomavirus loads and genotypes.Moving forward with human papillomavirus immunotherapies.DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection Cervical Carcinogenesis and Immune Response Gene Polymorphisms: A Review.Recent advances in understanding and preventing human papillomavirus-related disease.Electroporation-enhanced delivery of nucleic acid vaccines.Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner Clinical potential of electroporation for gene therapy and DNA vaccine delivery.Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy.Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.Current state in the development of candidate therapeutic HPV vaccines Immunotherapy against cancer-related viruses.Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.The current state of therapeutic and T cell-based vaccines against human papillomaviruses.Immunomodulatory Nanomedicine.Nucleic acid-based vaccines targeting respiratory syncytial virus: delivering the goods.Current status and future prospects for human papillomavirus vaccines.Targeting Persistent Human Papillomavirus Infection.A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.Therapeutic vaccines for high-risk HPV-associated diseases.Effects of Th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Therapeutic cancer vaccines.The perfect personalized cancer therapy: cancer vaccines against neoantigens.Vaccination-induced skin-resident memory CD8+ T cells mediate strong protection against cutaneous melanoma.Trial watch: DNA-based vaccines for oncological indications

P2860

Q26744094-CF45FFB7-7C91-47C7-BDF2-6264C9FCA040 Q26771981-0AEBEEB6-5744-44A9-AF61-9A97947D24D4 Q28069272-E6F728F2-1E37-412D-8B54-2CFFEBDF4ED7 Q28072532-ED4F77A7-F0A6-4057-8FC7-8016B570E1EA Q33907700-81269E02-F5B1-45D3-BB66-D2824B5F277C Q35861251-78EC1CC3-4F97-47F1-BCE9-C8D571C7CD4E Q37014047-0ECF936D-0EA2-40A5-BB60-37C6A12D9752 Q37135023-4F9E07AB-95FC-460A-8171-6E178BF46AC0 Q37395174-3828F6B3-1413-4BE9-8997-D17D00BE7CE1 Q37430280-EFCBFD5E-B7B1-4070-9BB1-B9E30720D196 Q37473299-0822EABF-B6B7-4A83-AF59-911752D8C35F Q37626311-1BB79D86-E067-4E28-89DF-010EAC46AD9D Q37661158-953D891B-C00C-411D-81AC-1377F27465D0 Q37709706-7F8C4B00-2710-4307-A7EF-362DD3CF41AA Q38285418-ACF4DC12-D381-43A3-A1F4-1DB103247D53 Q38619097-4BA70B95-02A1-4220-8663-9688445E13F3 Q38636510-9A2FCEF2-908F-4212-97B1-7CF9517F7F76 Q38644639-16D4C1C6-B38B-41B0-9DFF-98FADD52E1AA Q38730774-B40A91DD-B53D-4C45-B267-F80D598483DD Q38743922-EEC1BDCE-39FE-4033-9CCC-4BDF139CC5AB Q38778924-28BEE010-8465-4C21-A099-EC5CA49F4676 Q38835118-4BF80A59-237A-4C8D-B4AF-C068069FA5B3 Q39033576-3C05EC61-8B77-4F53-8280-CBB9A8B05F0A Q39224331-A39B3AC9-B280-41E7-9D73-B7A63EB56EB2 Q40053603-B03EB78B-C9BE-4742-A237-1C5EF1BD0F10 Q40056541-B4E4266D-69DA-48F1-8ED3-B7FAAEA45F5E Q40078375-65A80400-BB54-4DD1-A10F-02A995566382 Q40099137-0BB7E007-411A-4EC0-B980-88F93BD4EBF5 Q40306609-8D890732-6102-46C0-AB0A-45EF903356D8 Q41067857-9EB6A8E2-25D8-4FAE-BB45-8FBDFC64636F Q47224779-1EEEBBF6-387E-4589-9BCE-0F5E23A22DA4 Q47255618-B95EC195-B878-4F26-B315-C5A4FE22939A Q48349463-2EA37160-5F48-49D3-AF21-6A15CE6EBDC4 Q50115667-342EEEDD-81F9-4AEB-956D-33290A182A3C Q50988785-6D93E8FD-CFD4-4960-8770-7BA0D431F752 Q55001351-04F3F8A2-4608-4D55-8B52-778A878082F7 Q55122008-4AEB3E4E-F52D-4081-9D46-7E991853CD7F Q56893452-985AEE45-2450-490B-B32D-803ABFEC33B1

P2860

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients.

http://www.wikidata.org/entity/Q34453827

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@ast

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@en

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@nl

type

label

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@ast

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@en

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@nl

prefLabel

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@ast

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@en

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@nl

P1433

Q34453827-828AB03B-7B85-461E-917D-0D0F9CF50C47

P1476

Q34453827-92299594-4574-485D-92AA-6F43CAA2BA8C

P2093

Q34453827-039654D8-DD36-4113-B221-A5F2100792A8

Q34453827-0B1149FF-92A5-4C9D-98B7-B5DBCC0777C4

Q34453827-0CF008AE-5000-4758-BAE0-A9DC2CC00139

Q34453827-3329BC8B-1668-4A1F-BE86-AB74407C58F7

Q34453827-468DD8E0-00C9-4710-8DE2-5D813E09C296

Q34453827-4BABE4F1-7F4E-43E2-A477-287C6F158E51

Q34453827-62A855C7-79C1-4461-893D-CE0B620C1CED

Q34453827-693CA8C5-F571-49C1-953C-DADA68F3C20E

Q34453827-7035F115-9CB1-4B51-8EFF-3CC31ED3BB2C

Q34453827-72874560-3566-4647-BB68-CF66F32F1173

P2860

Q34453827-02C8C38F-B7C2-4E81-B42E-5A630F564214

Q34453827-08B9ECAB-B997-4B3F-AB4F-05C513489FFD

Q34453827-1313AFFF-3035-43EB-AC4B-885B44993E42

Q34453827-14A21AE2-60DB-4D2C-BBAC-C9FB6D25E87D

Q34453827-176A17B6-A4EF-4F79-920C-BA597260F4D7

Q34453827-1D08546B-70A6-4B09-B996-66DA6E2AD28B

Q34453827-1D6EC79B-8FE3-49EB-B903-93222F02C08A

Q34453827-205797E9-6224-424E-A4A3-0AD1DDA0B4AA

Q34453827-20C80D7A-672E-4296-AF13-1F6A69176094

Q34453827-20F9E32F-A154-4A3D-9E82-4287DE9A8AC0

P2888

Q34453827-CE260C45-FA13-49AF-A5AE-C759627237F9

P304

Q34453827-989F6FEF-27D7-4FD8-9808-01758F533507

P31

Q34453827-90ED011C-7987-4F0B-BDCA-EFC2A88ECAA8

P356

Q34453827-96BBA8A1-989B-4FB3-85FC-BB5EC011D7D3

P407

Q34453827-0C6BADBB-728C-4F4D-A272-464533C0B1F6

P478

Q34453827-B456A520-023E-4D64-8B11-CFC4059D6973

P577

Q34453827-3F580201-F46B-4DFB-8ED0-806937215CE3

P5875

Q34453827-4D795C93-736D-4B7A-AB74-19893CD44B6F

P6179

Q34453827-E08D8ED2-F7B5-4973-976C-B0EA5C55C9F6

P698

Q34453827-1B5475D9-B617-4FA6-B0C2-C8C5B94AFD58

P932

Q34453827-73E1A9A0-D098-4FAD-8A6A-0D184D1FEE77

P356

P1433

Nature Communications

P1476

Clearance of persistent HPV in ...... DNA vaccine in CIN3 patients.

@en

P2093

Chang-Woo Lee

http://www.w3.org/2001/XMLSchema#string

Charles D Surh

http://www.w3.org/2001/XMLSchema#string

Hyun Gul Yang

http://www.w3.org/2001/XMLSchema#string

Hyun-Tak Jin

http://www.w3.org/2001/XMLSchema#string

In-Ho Lee

http://www.w3.org/2001/XMLSchema#string

Jaehan Park

http://www.w3.org/2001/XMLSchema#string

Jong Sup Park

http://www.w3.org/2001/XMLSchema#string

Jung-Won Woo

http://www.w3.org/2001/XMLSchema#string

Ki Seok Park

http://www.w3.org/2001/XMLSchema#string

Ki-Heon Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor

Heterologous T cell immunity in severe hepatitis C virus infection

Solution Structure Analysis of the HPV16 E6 Oncoprotein Reveals a Self-Association Mechanism Required for E6-Mediated Degradation of p53

Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.

Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis.

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.

Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination.

Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3

Memory CD8 T-cell differentiation during viral infection.

P2888

P304

5317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS6317

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267738452

http://www.w3.org/2001/XMLSchema#string

P6179

1032023115

http://www.w3.org/2001/XMLSchema#string

P698

25354725

http://www.w3.org/2001/XMLSchema#string

P932

4220493

http://www.w3.org/2001/XMLSchema#string